GenSight Biologics S.A. (SIGHT.PA)
EUR 0.24
(0.63%)
EUR 0.24
(0.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.08 Million EUR | -64.97% |
| 2022 | 25.94 Million EUR | -54.21% |
| 2021 | 56.64 Million EUR | 19.61% |
| 2020 | 47.36 Million EUR | 45.8% |
| 2019 | 32.48 Million EUR | -12.16% |
| 2018 | 36.97 Million EUR | -40.56% |
| 2017 | 62.21 Million EUR | 5.03% |
| 2016 | 59.23 Million EUR | 63.12% |
| 2015 | 36.31 Million EUR | 145.07% |
| 2014 | 14.81 Million EUR | -21.49% |
| 2013 | 18.87 Million EUR | 31033.6% |
| 2012 | 60.61 Thousand EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 14.98 Million EUR | 0.0% |
| 2024 Q1 | 14.98 Million EUR | 64.1% |
| 2023 Q4 | 9.13 Million EUR | 0.0% |
| 2023 FY | 9.08 Million EUR | -64.97% |
| 2023 Q3 | 9.13 Million EUR | -45.42% |
| 2023 Q1 | 16.73 Million EUR | -35.5% |
| 2023 Q2 | 16.73 Million EUR | 0.0% |
| 2022 Q2 | 40.52 Million EUR | 0.0% |
| 2022 Q3 | 25.94 Million EUR | -35.99% |
| 2022 Q1 | 40.52 Million EUR | -28.46% |
| 2022 Q4 | 25.94 Million EUR | 0.0% |
| 2022 FY | 25.94 Million EUR | -54.21% |
| 2021 Q1 | 67.36 Million EUR | 42.23% |
| 2021 Q3 | 56.64 Million EUR | -15.91% |
| 2021 Q2 | 67.36 Million EUR | 0.0% |
| 2021 FY | 56.64 Million EUR | 19.61% |
| 2021 Q4 | 56.64 Million EUR | 0.0% |
| 2020 Q3 | 47.36 Million EUR | 74.43% |
| 2020 Q2 | 27.15 Million EUR | 0.0% |
| 2020 FY | 47.36 Million EUR | 45.8% |
| 2020 Q1 | 27.15 Million EUR | -16.41% |
| 2020 Q4 | 47.36 Million EUR | 0.0% |
| 2019 Q3 | 32.48 Million EUR | 4.88% |
| 2019 Q4 | 32.48 Million EUR | 0.0% |
| 2019 FY | 32.48 Million EUR | -12.16% |
| 2019 Q1 | 30.97 Million EUR | -16.25% |
| 2019 Q2 | 30.97 Million EUR | 0.0% |
| 2018 Q3 | 36.97 Million EUR | -29.96% |
| 2018 Q4 | 36.97 Million EUR | 0.0% |
| 2018 FY | 36.97 Million EUR | -40.56% |
| 2018 Q1 | 52.8 Million EUR | -15.13% |
| 2018 Q2 | 52.8 Million EUR | 0.0% |
| 2017 Q3 | 62.21 Million EUR | -16.01% |
| 2017 Q4 | 62.21 Million EUR | 0.0% |
| 2017 Q1 | 74.07 Million EUR | 25.06% |
| 2017 Q2 | 74.07 Million EUR | 0.0% |
| 2017 FY | 62.21 Million EUR | 5.03% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 FY | 59.23 Million EUR | 63.12% |
| 2016 Q4 | 59.23 Million EUR | -0.0% |
| 2016 Q3 | 59.23 Million EUR | 0.0% |
| 2015 Q3 | 36.31 Million EUR | 225.31% |
| 2015 Q1 | 11.16 Million EUR | -24.67% |
| 2015 FY | 36.31 Million EUR | 145.07% |
| 2015 Q2 | 11.16 Million EUR | 0.0% |
| 2015 Q4 | 36.31 Million EUR | 0.0% |
| 2014 FY | 14.81 Million EUR | -21.49% |
| 2014 Q4 | 14.81 Million EUR | 0.0% |
| 2014 Q3 | 14.81 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 FY | 18.87 Million EUR | 31033.6% |
| 2012 FY | 60.61 Thousand EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | 38.226% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 97.222% |
| Adocia SA | 24.95 Million EUR | 63.588% |
| Aelis Farma SA | 26.28 Million EUR | 65.424% |
| Biophytis S.A. | 11.93 Million EUR | 23.869% |
| Advicenne S.A. | 12.4 Million EUR | 26.759% |
| genOway Société anonyme | 31.84 Million EUR | 71.463% |
| IntegraGen SA | 8 Million EUR | -13.583% |
| Medesis Pharma S.A. | 1.92 Million EUR | -371.725% |
| Neovacs S.A. | 47.53 Million EUR | 80.883% |
| NFL Biosciences SA | 3.97 Million EUR | -128.855% |
| Plant Advanced Technologies SA | 14.91 Million EUR | 39.066% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -142.529% |
| Sensorion SA | 46.49 Million EUR | 80.456% |
| Theranexus Société Anonyme | 7.23 Million EUR | -25.55% |
| TME Pharma N.V. | 2.49 Million EUR | -264.793% |
| Valbiotis SA | 33.24 Million EUR | 72.669% |
| TheraVet SA | 7.53 Million EUR | -20.61% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 74.239% |
| DBV Technologies S.A. | 165.65 Million USD | 94.514% |
| Genfit S.A. | 173.87 Million EUR | 94.774% |
| GeNeuro SA | 6.31 Million EUR | -43.943% |
| Innate Pharma S.A. | 184.19 Million EUR | 95.067% |
| Inventiva S.A. | 69.13 Million EUR | 86.857% |
| MaaT Pharma SA | 42.93 Million EUR | 78.833% |
| MedinCell S.A. | 36.94 Million EUR | 75.406% |
| Nanobiotix S.A. | 93.89 Million EUR | 90.322% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 88.905% |
| Poxel S.A. | 4.82 Million EUR | -88.41% |
| Transgene SA | 45.21 Million EUR | 79.904% |
| Valneva SE | 469.39 Million EUR | 98.064% |